PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1995; 88(Suppl 25): 24–29.
PMCID: PMC1295055

Human recombinant DNase in cystic fibrosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (874K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. [PubMed]
  • CHERNICK WS, BARBERO GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics. 1959 Nov;24:739–745. [PubMed]
  • ARMSTRONG JB, WHITE JC. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet. 1950 Dec 9;2(6641):739–742. [PubMed]
  • CHERNICK WS, BARBERO GJ, EICHEL HJ. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients withcystic fibrosis. Pediatrics. 1961 Apr;27:589–596. [PubMed]
  • Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA. 1968 Jul 29;205(5):312–313. [PubMed]
  • Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis. 1968 Oct;98(4):697–698. [PubMed]
  • Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed]
  • Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. [PubMed]
  • Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. [PubMed]
  • Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. [PubMed]
  • Nickerson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Robertson G. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis. 1980 Dec;122(6):859–866. [PubMed]
  • Cooper PJ, Robertson CF, Hudson IL, Phelan PD. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 1990;8(1):16–22. [PubMed]
  • Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax. 1992 Sep;47(9):684–689. [PMC free article] [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press